Cross-sectional Study

Co-infection of SARS-CoV-2 with other viral respiratory pathogens in Yogyakarta, Indonesia: A cross-sectional study

Eggi Arguni a,⁎, Endah Supriyati b,c, Mohamad Saifudin Hakim d, Edwin Widyanto Daniwijaya d, Firdian Makrufardi e, Ayu Rahayu b,c, Anwar Rovik b,c, Utari Saraswati b,c, Farida Nur Oktoviani d, Nenes Prastiwi d, Titik Nuryastuti d, Tri Wibawa d, Sofia Mubarika Haryana e

⁎ Corresponding author.

E-mail addresses: eggiarguni@ugm.ac.id (E. Arguni), endah.supriyati@gmail.com (E. Supriyati), m.s.hakim@ugm.ac.id (M.S. Hakim), m.edwin.d@ugm.ac.id (E.W. Daniwijaya), firdianmakruf@gmail.com (F. Makrufardi), arahayu.id@gmail.com (A. Rahayu), anwarrovik.ps@gmail.com (A. Rovik), oesaraswati@gmail.com (U. Saraswati), farida.nur.o@ugm.ac.id (F.N. Oktoviani), nenesprastiwi@ugm.ac.id (N. Prastiwi), t.nuryastuti@ugm.ac.id (T. Nuryastuti), twibawa@ugm.ac.id (T. Wibawa), sofia.mubarika@gmail.com (S.M. Haryana).

1. Introduction

Since December 2019, the world has been dealing with a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak, which has had a devastating effect on public health as well as becoming a significant social and global economic burden. Indonesia is one of the countries most affected by Coronavirus Disease-2019 (COVID-19) with over 1.8 million confirmed cases and nearly 51,000 deaths as of June 3, 2021 (1). Yogyakarta is a remote province on the island of Java with a relatively high population density. During the same time period, 45,400 cases and 1200 deaths were reported in Yogyakarta [1].

In contrast to the first report in the early phase of the pandemic in Wuhan, China, which reported that co-infections with other respiratory pathogens in COVID-19 patients were infrequent [2], a study conducted in Northern California, USA revealed that the rates of viral respiratory co-infections had risen up to 21% [3].

Since SARS-CoV-2 have several similarities with common viral respiratory pathogens in terms of clinical presentation and modes of transmission, it is possible for co-infection to occur between SARS-CoV-2 and other viral respiratory pathogens. Recent studies showed that such co-infections may also aggravate the patients’ clinical condition [4–7]. The concerns of health authorities worldwide were directed toward the burden of these concomitant infections during the initial pandemic months and many clinical guidelines reflected this by indicating both
prevention of human respiratory syncytial virus (hRSV) and treatment of influenza for suspected cases [8].

Up to this moment, there is a lack of data regarding co-infection with other viral respiratory pathogens in patients with confirmed COVID-19 in Indonesia. In this brief report, we examine the frequency of respiratory viral co-infection among 125 SARS-CoV-2 positive nasopharyngeal swab samples at one of the COVID-19 referral laboratories located in Yogyakarta, Indonesia.

2. Methods

Positive respiratory specimens (nasopharyngeal swabs) of SARS-CoV-2 tested between April to May 2020 at the COVID Laboratory of the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada Yogyakarta were screened for other viral pathogens: human Influenza A and B viruses, hRSV, Human metapneumovirus (hMPV) and Adenovirus. Ethical approval was received from the Medical and Health Research Ethics Committee (KE/FK/0660/EC/2020). All methods for detection of SARS-CoV-2 with reverse transcription-polymerase chain reaction (RT-PCR) were performed correspondingly to the relevant guidelines. Proportion of specimens positive for SARS-CoV-2 and for each non-SARS-CoV-2 pathogen were identified. Data are presented with age group of patients and the proportion of gender. RNA from the each non-SARS-CoV-2 pathogen were identified. Data are presented

Table 1

| Target                     | Primer name | Sequence (5′-3′) | Gene Target |
|---------------------------|-------------|-----------------|-------------|
| Influenza A               | InfA_F      | GAC AAG ACC AAT CCT GTC ACY TCT G | M gene     |
|                           | InfA_R      | AAG GCT CTA GGC TGC AGT CC |            |
| Influenza B               | InfB_F      | TCG CTG TTT GGA GAC ACA AT | M gene     |
|                           | InfB_R      | TTC TTT CCC ACC GAA CCA |            |
| Respiratory Syncytial     | RSV_F       | ATG AAC AGT TTA ACA TTA CCA AGT | F gene     |
| Virus A, B                | RSV_R       | GTT TTT CCA TAG CAT |            |
| Adenovirus (Resp)         | AdvResp_F   | GAC AC CAG GCC TCG GGR TAY CTS AG | Hexon gene |
|                           | AdvResp_R   | GGA GCC ACV GTG GGR TT |            |
| Human Metapneumovirus     | hMPV_F      | AGC TTT AGT CAA TTC AAC AGA AG | F gene     |
|                           | hMPV_R      | CCT GCA GAT GTY GGC ATG T |            |

Table 2

| Parameter | N TOTAL | Inf-A Result | Inf-B Result | hMPV Result | hRSV Result | Adeno Result |
|-----------|---------|--------------|--------------|-------------|-------------|--------------|
| Age < 5   | 2       | 0            | 0            | 0           | 0           | 0            |
| 5 ≤ y.o.  | 6       | 3            | 1            | 1           | 0           | 1            |
| < 18      | 46      | 13           | 3            | 0           | 0           | 4            |
| 18 < y.o. | 45      | 11           | 5            | 0           | 0           | 5            |
| 60 ≤      | 30      | 5            | 7            | 0           | 0           | 0            |
| Total     | 125     | 32           | 16           | 1           | 0           | 10           |
| Sex Male  | 59      | 15           | 3            | 0           | 0           | 2            |
| Female    | 66      | 17           | 13           | 1           | 0           | 8            |
| Total     | 125     | 32           | 16           | 1           | 0           | 10           |

Table 3

| Samples | Age (year) | Viral respiratory pathogen                     |
|---------|------------|-----------------------------------------------|
| #33     | 57         | SARS-CoV-2 + Influenza A + Adenovirus         |
| #51     | 46         | SARS-CoV-2 + Influenza A + Adenovirus         |
| #54     | 15         | SARS-CoV-2 + Influenza A + Adenovirus         |
| #61     | 57         | SARS-CoV-2 + Influenza A + Adenovirus         |
| #79     | 57         | SARS-CoV-2 + Influenza A + Adenovirus         |
| #83     | 39         | SARS-CoV-2 + Influenza A + Adenovirus         |
| #116    | 71         | SARS-CoV-2 + Influenza A + Adenovirus         |

Notably, 9 (7.2%) patients had co-infection with more than two viruses (Table 3).

4. Discussion

There is existing evidence of pathogenic competition between respiratory viruses, including between human influenza viruses and seasonal human coronaviruses (OC43, HKU1, NL63, and 229E) [11–13]. Therefore, even in a pandemic situation, several viral respiratory pathogens should be considered, when establishing the initial etiology and appropriate treatment. At the population level, simultaneous detection of respiratory viruses, such as influenza and SARS-CoV-2, can be employed as an early prediction model of future outbreaks of both viruses.

Our study showed a higher prevalence of viral co-infection (47.2%) compared to the prevalence of 31.5% reported in Jiangsu Province, China [14]. Additionally, the prevalence was much higher compared to those reported in Northern California (21%) [3], Australia (8%) [15], Turkey (2%) [16], and Singapore (1.4%) [17]. The latest systematic review estimated that 3% of hospitalized patients with confirmed COVID-19 were also co-infected with another respiratory virus, mostly hRSV and human influenza A virus [18]. By using a test negative design, one study indicated that the risk of testing positive for SARS-CoV-2 was significantly lower among influenza positive cases [7]. Another study reported that <3% of those testing positive for SARS-CoV-2 had co-infection with Influenza A virus. This frequency was lower in SARS-CoV-2 negative patients in which 13% were influenza positive [19]. A similar interaction happens between influenza and other viruses, such as seasonal coronaviruses and rhinovirus [11,13,20]. SARS-CoV-2 apparently has a slower growth rate than influenza virus. The growth of SARS-CoV-2 is suppressed by the influenza virus if they both simultaneously infect the host. Co-infection between these two viruses would be more readily detected, if influenza virus infection followed SARS-CoV-2 infection [21].

This phenomenon suggests a pathogenic competition between those respiratory tract-infecting viruses. Furthermore, it is hypothesized that...
general and non-specific immune responses (such as interferon) against the first viral infection (i.e., influenza virus), may help inhibiting the secondary SARS-CoV-2 infection [22]. The increased risk of severe disease and mortality were also found to be associated with co-infection between SARS-CoV-2 and Influenza A virus, even though this appears not to be correlated to the independent effects of each virus [18].

Recent research in Indonesia reported the prevalence of influenza within severe acute respiratory infection (SARI) patients was 12.1% [23]. Even though the surveillance data for the seasonal incidence of influenza virus infection are lacking in Indonesia, influenza viruses and SARS-CoV-2 share the common route of transmission and similar clinical manifestations, during this pandemic, co-infection with these viruses should be carefully considered throughout the year.

In this study, we did not identify co-infection with hRSV, similar to another study in Brazil. That study did not find any co-infection with hRSV in the region which has a very well-defined and significant annual hRSV and influenza transmission [24]. This finding, again, alerts us to the hypothesis of a possible pattern of competition among respiratory viruses, but the public awareness of SARS-CoV-2 pandemic for transmission control such as using face mask, local social distancing, working from home, and the closing of schools and daycare centers can be associated with these observations.

hMPV co-infection was detected in only 1 sample (1/125). Previously, identification of co-circulation of hMPV and SARS-associated coronavirus during a nosocomial SARS-CoV outbreak raised the possibility of significant interaction [25]. hMPV transmission was reported as a serious outbreak in health care facilities [26]. Furthermore, this current study revealed the proportion of Adenovirus co-infection was around 8% of tested samples, which was similar with the pool proportion of Adenovirus co-infection in total viral detections reported in a systematic review [18].

Co-infection by two viral respiratory pathogens is prevalent, given similar routes and modes of transmission [27,28]. Nevertheless, early identification of coinfection is necessary given the differences in treatment and prognosis. Antiviral therapy is currently available for influenza virus infection (eg oseltamivir) as well as unlabeled experimental drugs (eg lopinavir/ritonavir and hydroxychloroquine) are becoming common practice in the treatment of COVID-19.

We acknowledge that our study was not without some limitations. All specimens tested in this study were only the SARS-CoV-2 positive samples with the result that we could not reveal the proportion of other viral pathogens in SARS-CoV-2 negative samples. Second, we could not analyze detailed information about epidemiology and clinical manifestations of patients since some information was not available in our laboratory. Third, all specimens tested for these other viral co-infections were from the second frozen-thawed samples, which could contribute to the failure to identify the viruses that originally may have been present at very low titer. Finally, we could not identify the sequential course of primary and secondary infections, so we are unable to explain the possible interaction.

Based on the result of this current study and similar other studies, the respiratory virus co-infections are more likely to occur during pandemic. The evident increase in risk among patients with co-infection has implications to support vaccination, not only for SARS-CoV-2 but also for influenza viruses. Simple laboratory diagnosis algorithm may be applied to screen viral co-infection and the testing for influenza viruses is important in hospital inpatients with COVID-19 to identify those who might have different responses to antiviral therapy.

5. Conclusion

In conclusion, an early and rapid identification of concomitant viral respiratory pathogens is important to improve diagnosis, clinical management and patients’ prognosis. Further research is required to better understand the pathogenic role of viral coinfection in respiratory disease.

Provenance and peer review
Not commissioned, externally peer reviewed.

Sources of funding
This study was funded by COVID Pemandatan UGM.

Ethical approval
This study has been approved by the Ethical Committee of Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital (KE/FK/0660/EC/2020).

Consent
Written informed consent was obtained from the patient for publication of this study and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contribution
Eggi Arguni and Endah Supriyati contributed equally to this work. All authors conceived the study, drafted and critically revised the manuscript for important intellectual content. Firdian Makrufardi critically revised the manuscript for important intellectual content. All authors read and approved the final draft. All authors facilitated all project-related tasks.

Registration of Research Studies
Research Repository Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada
Register Unique Identifying Number (UIN): 202202115

Guarantor
Eggi Arguni.

Declaration of competing interest
No potential conflict of interest relevant to this article was reported.

Acknowledgements
We gratefully acknowledge the COVID Laboratory Team, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada; and Conroy Surya Wijaya for administrative support. We also thank Erik Hookom for English proofreading and editing.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jamsu.2022.103676.

References
[1] Satuan Tugas Penanganan COVID-19, Peta Sebaran Kasus, 2021 [Internet]. Indonesia, https://covid19.go.id/peta-sebaran [cited 2021 Mar 30]. Available from:
[2] N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet 395 (10223) (2020) 507–513, https://doi.org/10.1016/S0140-6736(20)30211-7.
[3] D. Kim, J. Quinn, B. Pinsky, N.H. Shah, I. Brown, Rates of Co-infection between SARS-CoV-2 and other respiratory pathogens, JAMA 323 (20) (2020) 2085–2086, https://doi.org/10.1001/jama.2020.6266.
